The endogenous thyroid hormones L-thyroxine (T 4 ) and 3,5,3 0 -triiodo-L-thyronine (T 3 ) induce angiogenesis via an endothelial cell iodothyronine receptor on integrin aVb3. This receptor also exists on platelets. Diiodothyropropionic acid (DITPA) and GC-1, a noniodinated thyroid hormone analog, also induce angiogenesis. Here we examined the effects of iodothyronines (L-T 4 vs L-T 3 ) and analogs DITPA and GC-1 on human platelet function. Subthreshold aggregation of platelets obtained from healthy human donors was induced with collagen. Platelet activation (proaggregation) and adenosine triphosphate (ATP) secretion (degranulation) induced by L-T 4 , L-T 4 -agarose, L-T 3 , DITPA, or GC-1 were determined simultaneously. Platelet aggregation and ATP secretion induced by a subthreshold level of collagen were enhanced 3-fold by either L-T 4 or L-T 4 -agarose (0.01 mmol/L) as compared to control, whereas, L-T 3 , DITPA, or GC-1 had no effect under the same conditions. The platelet proaggregatory and degranulation effects of L-T 4 were blocked by the avb3 antagonist XT199 (0.1 mmol/ L) and by tetraiodothyroacetic acid (tetrac; 0.1 mmol/L). Tetrac inhibits binding of thyroid hormone analogs to the receptor on avb3 and lacks thyromimetic activity at this site; thus, the proaggregatory action of L-T 4 likely involves the cell surface receptor on integrin avb3. The thyroid hormone receptor (TR) on human platelets but not endothelial cells distinguishes among iodothyronines, reflecting quantitative differences in integrin sites on endothelial cells and platelets or qualitative differences in the phospholipids/protein microenvironment of endothelial and platelet membranes that can affect integrin function. Additional studies in different populations with larger sample sizes are warranted to determine the impact of the current findings on clinical interventions.
Introduction
Thyroid hormone has been reported to have a number of actions on blood elements. These include in vitro effects on superoxide production 1 and intracellular free calcium concentration 2 in human polymorphonuclear leukocytes and stimulation of calcium pump (Ca 2þ -adenosine triphosphatase [ATPase]) activity in the plasma membrane of enucleate human mature erythrocytes. 3, 4 Studies of effects of the hormone on blood platelets have suggested that thyroid hormone analogs are inhibitors of collagen-induced This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. platelet aggregation, 5, 6 but superphysiological concentrations of the hormones were used. 5, 6 Free thyroid hormone levels in patients with subclinical and overt hypothyroidism have been reported to be determinants of serum levels of soluble CD40 ligand 7 that is released by activated platelets. In addition, platelet 5 0 -nucleotidase activity is increased and decreased, respectively, in hyperthyroidism and hypothyroidism induced experimentally in rats. 8 We have recently shown that thyroid hormone is proangiogenic in the chick chorioallantoic membrane and human dermal microvascular endothelial cell tubule formation models [9] [10] [11] [12] , and that these actions are initiated at the plasma membrane, rather than the nuclear TR. The cell surface receptor is located on integrin avb3, near the Arg-Gly-Asp (RGD) recognition site that is important to integrin-extracellular matrix (ECM)-protein interactions. The proangiogenic actions of T 4 , T 3 , 9, 12 and other hormone analogs 10, 11, 13 have led us to consider the possibility that local intravascular administration of thyroid hormone might be useful in initiating neovascularization in the diseased coronary artery circulation or in large vessels elsewhere. 14 This consideration required that we examine these iodothyronines for actions on platelets. Of note is that platelets contain integrins, including avb3 [15] [16] [17] [18] . Were thyroid hormone analogs to activate platelets, iodothyronines would be undesirable as interventional proangiogenic agents. A procoagulant effect of circulating levels of the hormone, however, would be a regular asset to the process of wound healing. We show here that T 4 causes platelet aggregation in vitro that is associated with ATP release. However, T 3 and the nonhalogenated T 3 analog GC-1 did not promote platelet aggregation. DITPA, a thyromimetic agent that lowers circulating total cholesterol levels without cardiac chronotropism, 19 also had no effect on platelet aggregation.
Materials and Methods

Reagents
Thyroid hormone analogs, including unmodified L-T 4 , L-T 4 -agarose, L-T 3 , tetrac, and DITPA, were obtained from Sigma (Saint Louis, Missouri). GC-1 was kindly provided by Dr Scanlan (University of Oregon Health Sciences Center). XT199 is a proprietary inhibitor of ligand binding to the RGD recognition site on heterodimeric integrins and was developed by one of the authors (SAM). Collagen, other platelet agonists, and common reagents were obtained from Sigma.
Blood Sampling
Whole blood was drawn daily from 3 male and 3 female healthy donors (who were not on any medications, including aspirin) between the ages of 17 and 21 years into 4.5-mL Vacutainer vials with 3.8% buffered sodium citrate (Becton Dickinson, Rutherford, New Jersey). The blood was kept on a rocker to extend the life of the platelets, and experiments were done within 5 hours of phlebotomy.
Human Platelets
Platelets were studied in citrated whole blood obtained from healthy human donors under a protocol approved by the institutional review board of the Albany College of Pharmacy and Health Sciences. The Model 560 Whole-Blood Aggregometer and the associated Aggro-Link Software from the Chrono-Log Corporation were used in this study. Two electrodes are placed in diluted blood and an electrical impulse is sent from one to the other. As the platelets aggregate around the electrodes, the Chrono-Log measures the impedance of the electrical signal in ohms of resistance. A lumiaggregometer simultaneously measures aggregation and ATP secretion to provide a quantitative determination of second wave aggregation. Direct luminescent measurement of ATP secretion in blood provides unequivocal evidence of normal dense granule release and is a quantitative measure of platelet activation.
Platelet function was studied on a Chrono-log Electronics whole blood aggregometer as previously described. [20] [21] [22] Thyroid hormone analogs were then added at the concentrations cited and aggregation quantitated. For the control, 500 mL of whole blood, 500 mL of 0.9% saline, and a magnetic stir bar were mixed in a cuvette and heated for 5 minutes to 37 C. Subthreshold aggregation was induced with 5 mL of 1.0 mg/mL collagen type I and then measured for 8 to 10 minutes. The effects of L-T 4 , L-T 4 -agarose, L-T 3 and other thyroid hormone analogs on collagen-induced aggregation and ATP secretion were tested at 0.01 mmol/L.
Statistical Analysis
Statistical analysis was performed by one-way analysis of variance (ANOVA), using Statview software (Adept Scientific, Acton, Maassachusetts) and by comparing the mean + SD from each experimental group with its respective control group. Statistical significance was defined as P < .05.
Results
Platelet Aggregation
As shown in a representative of 6 experiments with 3 males and 3 females ( Figure 1A) , collagen stimulated platelet aggregation, decreasing impedance by 40%. L-Thyroxine (0.01 mmol/L) accelerated the decline in impedance attributable to collagen and enhanced the collagen-induced reduction in impedance to 60%. L-Thyroxine-agarose (0.01 mmol/L) was comparable to unmodified T 4 in its effect on platelet aggregation ( Figure 1B) . No further enhancement was shown at higher concentrations of L-T 4 or L-T 4 -agarose, up to 1.0 mmol/L (data not shown). L-thyroxine or L-T 4 -agarose did not affect platelet function in the absence of a subthreshold concentration of collagen.
In contrast, L-T 3 (Figure 2A ), DITPA ( Figure 2B ), and GC-1 (data not shown) at 0.01 to 1.0 mmol/L did not affect impedance. A collagen effect on aggregation was reproduced in the samples to which these iodothyronine analogs were added. XT199 or tetrac at 0.1 mmol/L inhibited the action of L-T 4 or L-T 4 -agarose on platelet aggregation (Table 1 ). These results are consistent with L-T 4 acting at the hormone receptor located at the RGD recognition site on integrin anb3. 9 In the absence of L-T 4 or L-T 4 -agarose, tetrac and XT199 had no effect on impedance (results not shown). hormone effect was blocked by tetrac and by XT199 ( Table 1 ). There was no effect of L-T 3 and DITPA on platelet ATP secretion (Figure 2A,B) . Similar lack of effect was also demonstrated with GC-1 (data not shown).
Platelet ATP Secretion
Discussion
Strong evidence for nongenomic actions is the effect of L-T 4 on cells that do not have a nucleus such as human platelets. In the current study, we demonstrated that the thyroid hormone L-T 4 enhanced platelet activation, an effect that appears to be initiated at the platelet avb3 integrin receptor. Interestingly, T 4 activated platelets, but not T 3 , even at hormone levels at which T 4 was active. This is consistent with the distinctive dissociation constants we have described for T 3 and T 4 at the integrin receptor. 9 Thyroxine covalently linked to agarose, which does not permeate the cell membrane, was as active as unmodified T 4 without permeating the platelets. The nonhalogenated T 3 analog GC-1 failed to activate platelets, and DITPA had no effect on platelet function. GC-1 and DITPA are thyroid hormone analogs undergoing trial as hypocholesterolemic agents, and the absence of effects on platelet function is desirable. These findings have implications for novel uses of thyroid hormone, which have been proposed as a consequence of the identification of the integrin 
Note: Tetrac, tetraiodothyroacetic acid; T 4 , thyroxine. a Data represent mean + SD, n ¼ 6. b P < .01.
receptor for the hormone. T 4 , T 3 , GC-1, and DITPA are iodothyronine analogs that have been shown to be proangiogenic. [10] [11] [12] Clinical applications of thyroid hormone as an angiogenic agent would be disadvantageous should the hormone promote blood platelet aggregation. The current studies indicate that local administration of T 4 would be contraindicated in the setting of ischemia in a limb but that T 3 , GC-1, and DITPA might be attractive. In contrast, if enhancement of angiogenesis in the context of clotting and wound healing is a goal, then testing of T 4 is appropriate. Platelet function in vivo has been repeatedly studied in the clinical setting as a function of thyroid hormone levels. [23] [24] [25] [26] The results have been inconsistent, probably reflecting differences in severity of hyperthyroidism and hypothyroidism and complicating illnesses, and have been based on different methods of assessment of platelet function. The current observations were conducted in vitro on platelets in whole blood obtained from healthy donors and with levels of added T 4 that approximate normal serum total hormone levels (10 -7 mol/L). However, the whole blood used in the current aggregometry studies contained thyroid hormone and circulating binding proteins for thyroid hormone. Thus, the levels of total T 4 in the measurement system were additive to endogenous hormone, doubling the latter. The concentration of T 3 in the samples tested was superphysiological when L-T 3 was added to endogenous hormone, but this level did not affect platelet function.
That proangiogenic thyroid hormone analogs can be distinguished according to their actions on platelet aggregation was initially surprising. In the cases of T 4 and T 3 , however, interactions with the integrin receptor in vitro are somewhat different. That is, there is a difference in affinity of each hormone for the integrin receptor site, 9 with avidity higher for T 4 . Computer modeling of the interactions of T 4 and T 3 with the receptor at the RGD recognition site on the integrin does indicates that the fit of the hormones may also be different. We have not yet modeled the interactions of DITPA and GC-1 with the receptor. Enhancement of angiogenesis by the action of thyroid hormone at the endothelial cell plasma membrane receptor is a complex process that depends on production of basic fibroblast growth factor (bFGF) and autocrine stimulation by bFGF of endothelial cell proliferation. 12 This process of FGF release and proliferation in endothelial cells requires several days. In contrast, platelet aggregation is a rapid process with a wholly different mechanism in a blood element that is an atypical ''cell.'' The microenvironment of the integrin that is important to the function of integrin avb3 28 is different in the membrane of the platelet compared to that of nucleated cells. Compared to the activity of the integrin receptor in intact endothelial cells, the insertion of the integrin into the platelet membrane differentially affects the ability of the receptor site to bind several thyroid hormone analogs, 9,10-13 as T 3 , DITPA, and GC-1 are active at the integrin receptor in endothelial cells but do not affect platelet function in vitro.
The potential impact of these data on future clinical interventions merits additional studies in different populations with larger sample sizes. L-Thyroxine administration in thrombosis-prone patients, such as those with factor V Leiden or prothrombin G20210A might be reconsidered in light of this preliminary investigation. Additionally, the use of high doses of T 4 in such patients to suppress thyrotropin (TSH) in thyroid cancer may pose a special risk. However, patients not known previously to be clot-prone might also be exposed to prothrombotic risk with high-dose T 4 . In those cases, L-T 3 appropriate regimens might be a safer alternative.
